ArticleNature communications2023
Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 46 citations in OpenAlex.
- Cardiac remodelling and dysfunction in cancer patients receiving cardiotoxic therapies: proteomic and metabolomic profiling.European heart journal · 2026Article
- Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.Nature communications · 2026Article
- Identifying druggable proteins of the association of chronotype on breast cancer using Mendelian randomization.Communications medicine · 2026Article
- Plasma proteome-metabolome signatures enable non-invasive early detection and lymph node risk stratification in breast cancer.Molecular cancer · 2026Article
- Adiposity and cancer: epidemiology, mechanisms and future perspectives.Nature metabolism · 2026Review
- Transcriptome predictors of second breast events in ductal carcinoma in situ: a case‒control study including Black and White women.Breast cancer research : BCR · 2026Article
- Cross-ancestry proteome-wide Mendelian randomization prioritizes 12 plasma protein candidates for breast cancer risk.medRxiv : the preprint server for health sciences · 2026Article
- Genetically predicted TTK inhibition and its association with reduced breast cancer risk: a two-step Mendelian randomization study of potential gut microbiome mediation.Clinics (Sao Paulo, Brazil) · 2026Article
- Promotion of breast cancer by the DNPH1 enzyme.iScience · 2026Article
- Genetic evidence for causal roles of circulating proteins on breast cancer susceptibility.iScience · 2026Article
- SELE is associated with reduced breast cancer susceptibility: Evidence from Mendelian randomization and single-cell transcriptome.Translational oncology · 2026Article
- Identification of Biomarker in Kidney Stone Disease by Integrating Transcriptomics and Olink Proteomics: A Case-Control Study.Journal of inflammation research · 2026Article
- From proteome-wide Mendelian randomization and multi-omics integration to functional validation: TGFB3 as a prioritized candidate in gastric adenocarcinoma.Frontiers in oncology · 2026Article
- Mendelian randomization and bioinformatics analysis identify the association between plasma proteins and cataract.Scientific reports · 2025Article
- Mendelian randomization analysis integrating GWAS and eQTL data identified potential regulatory genes associated with prostate cancer in neural cells.Discover oncology · 2025Article
- Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis.British journal of cancer · 2025Article
- A Multi-omics Exploration Revealing SLIT2 as a Prime Therapeutic Target for Peripheral Facial Paralysis: Integrating Single-Cell Transcriptomics and Plasma Proteome Data.Cellular and molecular neurobiology · 2025Article
- Leveraging genetic data for female breast cancer prevention and therapy: Perspectives from Mendelian randomization.iMetaOmics · 2025Article
- The plasma proteome and breast cancer risk.Breast cancer research : BCR · 2025Article
- Large-scale plasma proteomics uncovers novel targets linking ambient air pollution and depression.Molecular psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 4 countries.
Funding
Abstract
Biomarkers for early detection of breast cancer may complement population screening approaches to enable earlier and more precise treatment. The blood proteome is an important source for biomarker discovery but so far, few proteins have been identified with breast cancer risk. Here, we measure 2929 unique proteins in plasma from 598 women selected from the Karolinska Mammography Project to explore the association between protein levels, clinical characteristics, and gene variants, and to identify proteins with a causal role in breast cancer. We present 812 cis-acting protein quantitative trait loci for 737 proteins which are used as instruments in Mendelian randomisation analyses of breast cancer risk. Of those, we present five proteins (CD160, DNPH1, LAYN, LRRC37A2 and TLR1) that show a potential causal role in breast cancer risk with confirmatory results in independent cohorts. Our study suggests that these proteins should be further explored as biomarkers and potential drug targets in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.